Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy.
Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the subcutaneous route, according to a news release.
The patent applies to Bexson’s ketamine formulation tuned to the pH and osmolality of subcutaneous tissue. At the same time, it also applies to racemic ketamine and the R or S enantiomers as Bexson seeks to enable its subcutaneous ketamine delivery platform designed to manage pain disorders and mental health conditions.
Bexson and the FDA are currently working together as the company prepares for clinical trials that will evaluate the subcutaneous delivery of its ketamine formula, while it partnered with Stevanato Group to develop a wearable patch pump to allow for controlled delivery from a pre-filled, pre-sterilized wearable device.
Other formulation applications include further non-oral delivery solutions, like new chemical entities and research chemicals in the psychedelic medicine space.
“This technology provides a great new benefit for patients. We believe that the subcutaneous route of administration is perhaps the best method to deliver a controlled substance in a controlled manner,” Bexson co-founder & CSO Dr. Jeffrey Becke said in the release. “Ketamine is just one compound to which we can apply our formulation technology. We look forward to developing additional therapies to improve the viability of exciting controlled substances, including psychedelics and empathogens, for health conditions like chronic pain, addiction, PTSD and depression.”
